PURPOSE Two anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies are approved
for diffuse large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel; …

The B cell receptor (BCR) signaling pathway is functional and has critical cell survival
implications in B cell malignancies, such as chronic lymphocytic leukemia (CLL). Orally …

The introduction of chemoimmunotherapy and more recently the implementation of novel
agents into first-line and relapse treatment have substantially improved treatment outcomes …

Follicular lymphoma (FL) is traditionally considered treatable but incurable. In March 2021,
the US Food and Drug Administration approved the use of chimeric antigen receptor (CAR) …

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) achieves
durable remissions, with flattening of the progression-free survival (PFS) curve in patients …

The ALLIANCE A041202 trial found that continuously administered ibrutinib in the first-line
setting significantly prolonged progression-free survival compared with a fixed-duration …

PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and
dexamethasone (DRd) significantly prolonged progression-free survival in transplant …

The phase 3 VIALE-A trial reported that venetoclax in combination with azacitidine
significantly improved response rates and overall survival compared with azacitidine alone …

Though the chronic lymphocytic leukaemia (CLL) management options in India are still
limited compared to the novel drug options in resource-rich settings, the availability of less …

BACKGROUND: Chronic lymphocytic leukemia (CLL) is a significant health and economic
burden in the United States. Treatments include chemoimmunotherapy, such as …